Clinical Trial Update: Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on botulinum toxin type A for foot dystonia-associated pain in Parkinson's disease across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystonia
• Parkinson Disease

Drugs mentioned

• Botulinum toxin type A (botulinum toxin type A)

Snippet

Sponsor: University of Calgary | Conditions: Dystonia Disorder, Parkinson Disease | Phase 2, Phase 3 | Status: UNKNOWN